fda bpc-157 compounding restrictions Is Legal in 2026? Status Explained FDA panel to consider easing

1 Press release, July 3, 2026, ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI 2 Press Release, July 5, 2023, ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing 3 Press Release, July 25, 2025, ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T2D 4 Press Release, October 15, 2025, ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T1D 5 GMP = Good Manufacturing Practices 6 P ress Release, November 12, 2025, ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity - AdoXLong - and Provides an Update on its BioChaperone Platform Adocia Olivier Soula CEO [email protected] +33 (0)4 72 610 610 www.adocia.com Maarc Adocia Press & Investor Relations Bruno Arabian Yasmine Duval Thomas Rolnik [email protected] + 33 (0)6 87 88 47 26 View source version on businesswire.com: The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties

Fosgonimeton is a structurally distinct small-molecule prodrug developed by Athira Pharma

FDA concluded there is insufficient clinical safety information to characterize its human safety profile, and found no studies administering it to humans by the proposed routes

Choose packaging that keeps temperatures from changing too often as little as possible, like aliquoted vials instead of large cases